Nucala® (mepolizumab) – New indication
September 25, 2020 - The FDA announced the approval of GlaxoSmithKline’s Nucala (mepolizumab), for the treatment of adult and pediatric patients aged 12 years and older with hypereosinophilic syndrome (HES) for 6 months without an identifiable non-hematologic secondary cause.
Top